Clinical Trial

Escitalopram for Agitation in Alzheimer's Disease

Study acronym: S-CitAD
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-04-06; most recent amendment 2026-02-05.
Status change: Active, Not Recruiting → Completed 2026-02-05
Status change: Recruiting → Active, Not Recruiting 2024-02-28
Status change: Not Yet Recruiting → Recruiting 2017-12-11
Trial Details
NCT Number NCT03108846
Lead Sponsor JHSPH Center for Clinical Trials
Collaborators: National Institute on Aging (NIA)
Conditions Dementia
Enrollment 187 participants
Start Date 2018-01-03
Primary Completion 2024-04-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2025-01-31